DLA Piper has advised BrainCool AB (publ) ("BrainCool") in connection with BrainCool's securement of external financing through issuance of convertible notes with warrants attached. These will be delivered in several tranches of a total amount of SEK 100 million through convertible notes, and an additional SEK 80 million through warrants spread over 36 months.

The tranches are subscribed by the European Select Growth Opportunities Fund, focusing on technology and healthcare small cap companies presenting a strong growth potential. In connection with this transaction, BrainCool will also issue free warrants to its existing shareholders to protect them against dilution. The warrants will be admitted to trading on Aktietorget.

BrainCool is an innovative medical device company that develops, markets, and sells leading medical cooling systems for indications and areas with significant medical benefits within the healthcare sector. BrainCool's share is listed on Aktietorget.

The DLA Piper team based in Stockholm consisted of Corporate partner Peter Näslund and Corporate associates Louise St Cyr Linnarsson and Hanna Myhrman.